Grant-backed growth Scanogen recently secured a $2.9M NIH grant to advance culture-free diagnostics for bloodstream yeast infections, highlighting a credible government-backed funding runway and potential for expanded research collaborations and contract development opportunities.

Point-of-care The core focus on rapid, sample-to-answer point-of-care diagnostics for bloodstream infections suggests opportunities to partner with hospitals, urgent care networks, and blood culture centers seeking faster pathogen detection and reduced turnaround times.

SMOLT advantage Proprietary Single Molecule Tethering technology positions Scanogen to differentiate in ultra-sensitive biomolecule detection, presenting a sales angle with premium diagnostic platforms for high-value infectious disease assays and regulatory clearances.

NIH credibility More than twenty million dollars in NIH funding across its projects signals strong validation to potential customers and strategic collaborators, aiding in credibility when approaching larger healthcare systems and grant-driven procurement programs.

Growing footprint With a lean team (11-50 employees) and multi-million revenue range, there is a clear path for scalable partnerships, channel strategies, and early-adopter pilot programs with compatible manufacturers or distributors in the medical equipment ecosystem.